Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.40 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5240232 | 0.93 | CYP24A1 (0.44) | EGFRCYP24A1CYP27A1CYP26A1CYP19A1 | |
| SCHEMBL5319795 | 0.84 | CYP19A1 (0.44) | CYP19A1METAP1NPC1RAB9A | |
| SCHEMBL12698728 | 0.80 | CYP24A1 (0.46) | CYP24A1CYP27A1CYP26A1CYP19A1KDM4E | |
| SCHEMBL15028655 | 0.79 | CYP24A1 (0.47) | CYP24A1CYP27A1CYP26A1CYP19A1ALDH1A1 | |
| SCHEMBL16567983 | 0.79 | MAOA (0.48) | EGFRCYP24A1CYP27A1CYP26A1CYP19A1 | |
| SCHEMBL5238881 | 0.78 | ALK (0.38) | EGFRCYP19A1KDM4EALDH1A1GLA | |
| SCHEMBL3654990 | 0.76 | CYP24A1 (0.48) | CYP24A1CYP27A1CYP26A1CYP19A1KDM4E | |
| SCHEMBL13885522 | 0.76 | CYP24A1 (0.48) | CYP24A1CYP27A1CYP26A1CYP19A1KDM4E | |
| SCHEMBL15263331 | 0.75 | CYP24A1 (0.51) | CYP24A1CYP27A1CYP26A1CYP19A1KDM4E | |
| SCHEMBL9995710 | 0.74 | MAPK14 (0.47) | CYP24A1CYP27A1CYP26A1CYP19A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761513-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | Wyeth (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006007503-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | WYETH (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | ESR1, ESRRA, ESR2 | EGFR 30/4885CYP24A1 609/4885CYP27A1 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.